Pàgina inicial > Resultats de la cerca: Phase I/II trial
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
12 p, 823.0 KB Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation / Hodkinson, Brendan P. (Oncology Translational Research (Estats Units d'Amèrica)) ; Schaffer, Michael (Oncology Translational Research (Estats Units d'Amèrica)) ; Brody, Joshua D. (Icahn School of Medicine at Mount Sinai (Estats Units d'Amèrica)) ; Jurczak, Wojciech (Maria Sklodowska-Curie National Research Institute of Oncology) ; Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ; Ben-Yehuda, Dina (Hadassah-Hebrew University Medical Center) ; Avivi, Irit (Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine) ; Forslund, Ann (Bristol-Myers Squibb) ; Özcan, Muhit (Ankara University School of Medicine) ; Alvarez, John (Janssen Research & Development, Spring Housen (Estats Units d'Amèrica)) ; Ceulemans, Rob (Translational Medicine, Janssen Research & Development) ; Fourneau, Nele (Translational Medicine, Janssen Research & Development) ; Younes, Anas (Memorial Sloan Kettering Cancer Center) ; Balasubramanian, Sriram (Janssen Research & Development (Estats Units d'Amèrica)) ; Universitat Autònoma de Barcelona
We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002 phase I/IIa study, using programmed death ligand 1 (PD-L1) immunohistochemistry, whole exome sequencing (WES), and gene expression profiling (GEP). [...]
2020 - 10.1016/j.tranon.2020.100977
Translational Oncology, Vol. 14 (december 2020)  
Registre complet - Creative Commons
2.
8 p, 455.0 KB Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Keedy, Vicki (Vanderbilt University Medical Center) ; Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia) ; Shepherd, Frances A. (University of Toronto) ; Insa, Amelia (Hospital Clínic Universitari (València)) ; Brown, Holly (Merck & Co., Inc., Whitehouse Station) ; Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station) ; Sathyanarayanan, Sriram (Whitehouse Station, NJ USA) ; Reilly, John F.. (Merck & Co., Inc., Whitehouse Station) ; Mauro, David (Merck & Co., Inc., Whitehouse Station) ; Hsu, Karl (Sanofi Aventis) ; Yan, Li (Merck & Co., Inc., Whitehouse Station) ; Universitat Autònoma de Barcelona
We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC). [...]
2014 - 10.1186/2162-3619-3-26
Experimental Hematology & Oncology, Vol. 3 (november 2014)  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem